

Technical Data Sheet: A549-LUC2

ATCC [®] Number	CCL-185-LUC2™
Organism	Homo sapiens
Tissue/Disease Source	Malignant Melanoma
Product Description	A549-Luc2
Application	Excellent signal/background ratio and stable Luciferase expression make this cell line ideal for in vivo bioluminescence imaging of xenograft animal model to study human cancer and monitor activity of anti-cancer drug. It also can be used in cell-based assays for cancer research.




Figure 1: *In vivo* detection of luciferase activity of A549-Luc2. A549-Luc2 cells (3 x 10⁶) were injected subcutaneously into the dorsal region near the thigh of female nude mice. Tumor growth was monitored weekly using a Xenogen IVIS Spectrum. *In vivo* bioluminescence imaging demonstrated the progression of tumors.




Figure 2: Cell Morphology of A549 parental and A549-Luc2. Cells were maintained in ATCC recommended culture conditions. Cell morphology was observed under Nikon[™] microscopy and images were captured by Zeiss[®] digital camera.




Figure 3: Linearity of luminescence and *in vitro* **quantification of luciferase activity of A549-Luc2.** Cells were seeded in a 96-well plate at indicated cell numbers per well, and Bright-Glo (Promega) was added to the indicated wells. The luminescence of the plate was read within 10 minutes using a luminescence plate reader (A) and determined to have a linear correlation of bioluminescence intensity with cell numbers. (B) The plate was imaged using a Xenogen IVIS Spectrum to quantify that photons emitted per cell.

These products are for laboratory use only. Not for human or diagnostic use. ATCC products may not be resold, modified for resale, used to provide commercial services, or to manufacture commercial products without prior ATCC written approval.

^{© 2018} American Type Culture Collection. The ATCC trademark and trade name, and any other trademarks listed in this publication are owned by the American Type Culture Collection unless indicated otherwise.